Skip to content
Esta página está disponible en españolCambiar →
GestorLensSign up

OKYO Pharma (OKYO): which funds own it

Health Care →(by SIC code, unreviewed)Data as of Jun 30, 2026 (Q2 2026) · updated on Nov 6, 2026

A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.

Follow OKYO for free
Share

Sections with a free account

1 concentrated manager holds it (+1 vs last quarter) with a median weight of 0.1%. 6 officers or directors bought in 6 months.

Who owns OKYO Pharma?

Holders that filed a Schedule 13D or 13G with the SEC for owning more than 5% of the shares: Chernett Jorey (13G/A filed Feb 13, 2026), Sirenia Capital Management (13G filed May 15, 2026), Woodline Partners (13G filed May 15, 2026) and Laura Natalia Monica Fonda (13G filed Oct 29, 2025). Cerrone Gabriele M is listed on Form 4 filings as an owner of more than 10%. As of Jun 30, 2026, the largest holders reported on Form 13F were Woodline Partners (3.7 million shares), Stonepine Capital Management (862,996 shares) and Maven Securities (809,317 shares).

Which institutions hold the most OKYO Pharma shares?

Per Form 13F filings as of Jun 30, 2026:

  1. 1. Woodline Partners: 3.7 million shares
  2. 2. Stonepine Capital Management: 862,996 shares
  3. 3. Maven Securities: 809,317 shares
  4. 4. Balyasny Asset Management: 580,596 shares
  5. 5. Opaleye Management: 375,204 shares
  6. 6. UBS Group: 55,009 shares
  7. 7. XTX Topco: 37,769 shares
  8. 8. Choreo: 33,255 shares
  9. 9. Quantinno Capital Management: 33,255 shares
  10. 10. Cerity Partners: 12,812 shares

Sources:13G/A by Chernett Jorey (Feb 13, 2026) ↗13G by Sirenia Capital Management (May 15, 2026) ↗13G by Woodline Partners (May 15, 2026) ↗13G by Laura Natalia Monica Fonda (Oct 29, 2025) ↗All of the company's proxy statements on EDGAR ↗

We hold 13D and 13G filings made since Dec 23, 2024: a holder above 5% that has not filed since then does not appear here.

Concentrated managers
1
All 13F: 19
Consensus
—
No score: it needs 5 or more concentrated managers
Price at Jun 30, 2026 (per 13F)
$1.5
-6.8% in the quarter · reported value ÷ shares, not the quote · See current quote ↗

Quarter flow (concentrated managers)

Change in managers (0 → 1): 1 opened · 0 exited = +1

Net flow in the quarter: +$563K (+375 K shares) · bought $563K and sold $0Shares concentrated managers added minus those they cut, valued at the 13F quarter-end implied price, not each trade's price. It is a different measure from the change in managers: the two can have opposite signs.

Concentrated managers holding it

Up to 15, sorted by position value. The percentage is the weight in each manager's portfolio.

Largest holders of OKYO (all 13F filers)

The 10 13F filers with the most shares as of Jun 30, 2026, whatever their type (index firms usually come first). “Change”: shares added or cut versus the previous quarter, split-adjusted; “no data” = there is no comparable portfolio for the previous quarter (no filing, or a filing with its holdings under confidential treatment). “% of the company” only where shares outstanding are up to date. Entities of the same group file separately and some 13F filings include other managers: there may be double counting. With a free account: the top 25, the largest buyers and the largest sellers.

Insiders (Form 4)

Officers and directors who bought (6 m)
6
Amount (6 m)
$136K
CEO/CFO bought (12 m)
Yes

10% owners who bought (6 m): 0

Open-market purchases, excluding 10b5-1 plans. Officers and directors only; joint filers of the same purchase count as one. 10% owners with no role are shown separately. 0 = nobody bought; “no data” = we do not have its Form 4 filings.

Each of the company's Form 4 filings, on EDGAR ↗Latest trades, with date and filing →

Above 5% (13D/13G)

Disclosed stakes, with their amendments. A filing is not always a purchase: there are also reductions and changes of filing entity.

This list may be incomplete: we hold 13D and 13G filings made since Dec 23, 2024. A holder above 5% that has not filed anything since then is not shown here.

Above 5% over time (13D/13G)

Each holder with its filings in order. History since December 2024.

This company filed no 8-K forms in the last year. Foreign companies listed in the US (ADRs) report material events on forms 6-K and 20-F, and ETFs and funds do not file 8-Ks. If it is a foreign company listed in the US through ADRs (American Depositary Receipts), what trades are bank-issued certificates that represent shares from its home market. See its filings on EDGAR ↗

Other Health Care stocks in managers' portfolios

Same sector and a similar number of concentrated managers holding them. It is a list to keep exploring, not a recommendation.

All of Health Care →

Follow OKYO for free

If someone reports a 5%+ stake, we email you (if you turn it on). And when you come back, see whether concentrated managers got in or out. No credit card.

Follow OKYO